Karydas Daphneinsider trades
In SEC Form 4 filings, Karydas Daphne is listed as Director of Mineralys Therapeutics, Inc. (MLYS). In the last 90 days, Karydas Daphne sold $85.7K of Mineralys Therapeutics, Inc. (MLYS) on the open market and bought none. The sale was reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| MLYSMineralys Therapeutics, Inc. | Director | 3 | Sep 17 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-17
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| MLYSMineralys Therapeutics, Inc. | Sep 15 | Sep 17 | M | 3,000 | $12.02 | $36,060 | 9,200 | Yes | Form 4 |
| MLYSMineralys Therapeutics, Inc. | Sep 15 | Sep 17 | S | 3,000 | $28.58 | Sale −$85,740 | 6,200 | Yes | Form 4 |
| MLYSMineralys Therapeutics, Inc. | Sep 15 | Sep 17 | M · derivative | 3,000 | $12.02 | $36,060 | 35,000 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.